Develops and sells branded medicines for rare or unaddressed conditions to healthcare providers and hospitals, often through medicine distributors.
10-K for FY2025, filed Apr 15, 2026We develop, manufacture and commercialize a portfolio of branded therapeutics for the treatment of rare or unaddressed diseases in the…View ↗
We promote our products directly to physicians in office settings, hospitals, and ambulatory surgical centers across our key therapeutic…View ↗
We market our products to physicians (including rheumatologists, ophthalmologists, hepatologists, nephrologists, neurologists…View ↗
The company markets products to physicians and other healthcare providers; pharmacies, hospitals and institutions buy directly in some cases, while other sales go through wholesalers and specialty distributors. It also contracts with payer groups to set product pricing and support access.
10-K for FY2025, filed Apr 15, 2026We promote our products directly to physicians in office settings, hospitals, and ambulatory surgical centers across our key therapeutic…View ↗
The Company sells its products through independent channels which are considered its customers, including direct to retail pharmacies…View ↗
We market our products to physicians (including rheumatologists, ophthalmologists, hepatologists, nephrologists, neurologists…View ↗
10-K for FY2025, filed Apr 15, 2026
Successor Predecessor Year Ended December 31, 2025 Year Ended December 27, 2024 Period from November 15, 2023 through December 29, 2023…View ↗
Not on paper. It lost $489.5M in FY2025, but brought in more cash than it spent: $142.1M of free cash flow.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$96.1MView ↗
8-K, filed Aug 11, 2026
Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year…View ↗
8-K, filed Aug 3, 2026
On July 31, 2026, Keenova Therapeutics plc (the “Company”) closed the previously disclosed sale of its Percocet and Endocet businesses (the…View ↗
Branded focus
The older report described branded specialty medicines alongside specialty generics and active pharmaceutical ingredients. The latest report centers the business on branded therapeutics after separating its generic pharmaceuticals and sterile injectables businesses into Par Health.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Apr 15, 2026Specialty Brands includes innovative specialty pharmaceutical brands; and Specialty Generics includes niche specialty generic drugs and…View ↗
Our business markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology…View ↗
Our Specialty Generics segment is focused on providing our customers high-quality specialty generic drugs and APIs. Specialty Generics…View ↗
Loading...